In 2025, Caliway Biopharmaceuticals disclosed key data related to its energy management practices, providing transparency into its operational energy use in line with recognized sustainability reporting frameworks.
Caliway Biopharmaceuticals disclosed progress toward renewable energy adoption, highlighting the share of total energy sourced from renewable versus non-renewable sources.
| Metric (GJ) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Energy Consumption | 4,683a | 5,395a | 4,854a | |
Non-Renewable Energy Consumption | 4,683a | 5,395a | 4,854a | |
Renewable Energy Consumption | 0a | N/A | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, Caliway Biopharmaceuticals consumed a total of 4,683.03 Gigajoules of energy across its operations. Of this total, 0% was sourced from renewable energy, either derived from natural resources like biofuels, biomass, or biogas, or generated using renewable technologies such as solar or wind power. The remaining 100% was classified as non-renewable energy, coming from fossil-based fuels such as coal, natural gas, or crude oil, or from non-renewable generation technologies like nuclear power.a
In 2025, Caliway Biopharmaceuticals consumed a total of 4,683.03 Gigajoules of energy, of which 0% was derived from renewable sources, including biofuels, biomass, biogas, solar, and wind power.a
This low level of renewable energy use highlights a heavy reliance on fossil fuels or other non-renewable sources, suggesting that Caliway Biopharmaceuticals has considerable room to improve its energy sustainability strategy.
Since 2023, Caliway Biopharmaceuticals's total energy consumption decreased by 3.53%, including a further 13.19% drop in 2025, highlighting a continued decline in energy use.a